trending Market Intelligence /marketintelligence/en/news-insights/trending/wkHouuYOJ1oL21A5NpqyPw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Sanofi, Regeneron report positive phase 1 data for cancer treatment

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Sanofi, Regeneron report positive phase 1 data for cancer treatment

Sanofi and Regeneron Pharmaceuticals Inc. reported positive preliminary results from the phase 1 trial of REGN2810 in patients with advanced cutaneous squamous cell carcinoma, or CSCC, a type of skin cancer.

Under the trial, treatment with REGN2810 resulted in an investigator-assessed overall response rate of 46.2% and a disease control rate of 69.2%. The median progression-free survival and overall survival were not reached at the data cutoff date with a median follow-up of 6.9 months, the company said in a news release.

Further, one patient experienced progressive disease during treatment of the drug after the initial response, while two patients were not evaluable due to death unrelated to the treatment.

REGN2810 is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. The treatment is also being investigated in a phase 2 trial that is currently enrolling CSCC patients.